Medicxi
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Private Equity, Venture Capital, Biopharma, Biotechnology, Life Science
Stage Focus
Seed, Early Stage, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed, Pre-Seed, Series A, Series B, Series C & Beyond
Geographical Focus
United States, United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Luxembourg, Ireland, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Greece, Norway, Finland, Poland, Czech Republic, Romania
Industries Focus
- Healthcare
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Life Science
- Medical Research
- Clinical Trials
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Immunology
- Genomics
- Healthcare IT
- Biopharmaceuticals
- Biopharma
Investment Size:
3,000,000 to 50,000,000 USD
Investor Details Founded: 2016
Medicxi is a European life sciences venture capital firm specializing in early-stage investments in biotechnology and pharmaceutical companies across Europe and the United States. The firm focuses on creating and investing in companies along the full drug development continuum, from early discovery to late-stage therapeutics. Medicxi's mission is to address unmet medical needs by supporting innovative drug hunters and entrepreneurs in developing transformative therapies for patients.
The firm's investment strategy is centered around an 'asset-centric' model, emphasizing the development of specific therapeutic assets rather than broad platform technologies. This approach has led to the creation of 16 new companies since its previous fundraise, including Ottimo Pharma and Curevo Vaccine. Notable exits from the portfolio include Vicebio, acquired by Sanofi for $1.6 billion, and Versanis Bio, acquired by Eli Lilly for $1.9 billion.
Medicxi's team comprises professionals with extensive scientific, medical, and operational experience, having invested in over 89 innovative biopharma companies and achieved 32 exits through IPO and M&A. The firm has raised multiple funds, with the most recent being Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The firm's investors include global pharmaceutical companies such as GlaxoSmithKline, Johnson & Johnson Innovation, Novartis, and Verily (an Alphabet company).
Requirements
- Focus on life sciences sector
- Clear product vision addressing unmet medical needs
- Early and late-stage therapeutics
- Alignment with Medicxi's 'asset-centric' investment model
- Innovative biotechnology companies with clear product visions
- Focus on transformative therapies addressing unmet medical needs
- Early-stage companies across Europe and the United States
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Centessa Pharmaceuticals
- Molecular Partners
- Minerva Biosciences
- Villaris Therapeutics
- MiroBio
- Versanis Bio
- Ottimo Pharma
- Curevo Vaccine
- Vicebio
- Vaxcyte
- Merus
- Abivax
- Cellzome
- PanGenetics
- XO1
- Minerva Neurosciences
- Padlock Therapeutics
- Impact Biomedicines
- Adaptive Biotechnologies
- Genmab
- Micromet
- Egalet
- Versartis
Mentioned In
-
$49.95
-
$19.95
-
$24.95
-
$19.95
-
$19.95
-
$24.95
-
$39.95
-
$99.00
Claim this Investor
Are you an official representative of Medicxi?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim